AI Cardiology in 2026: AliveCor, Eko, HeartFlow, Cleerly, Caption

A sixty-two-year-old man with atypical chest pain sees his US primary-care physician on a Tuesday. He gets a 1.5mm slice coronary CT angiogram on Wednesday at the local imaging centre. By Friday morning the cardiologist has a HeartFlow FFR-CT analysis quantifying the haemodynamic significance of a mid-LAD stenosis, a Cleerly plaque-characterisation report showing low-attenuation plaque burden, and a clear decision: optimal medical therapy and a six-month follow-up rather than invasive catheterisation. Five years ago this patient was getting a catheter. In 2026 he is not, because the non-invasive AI-augmented pathway has matured.

Cardiology AI in 2026 is broad and deep. It spans wearables and consumer-grade ECG monitoring (AliveCor, Apple, Samsung, Fitbit), AI-augmented stethoscopes (Eko), AI guidance for non-expert echocardiography acquisition (Caption Health, now part of GE), and the sophisticated coronary imaging AI from HeartFlow and Cleerly that is changing the cath-lab referral pattern. This post walks through the vendor landscape, the evidence base, the integration realities, and where the real clinical gains are.

ECG and rhythm detection: wearables and clinical-grade#

AliveCor KardiaMobile — the original FDA-cleared single-lead and six-lead consumer ECG — continues to anchor the consumer-clinical bridge. Their AI detects atrial fibrillation, bradycardia, tachycardia, and a growing set of arrhythmias. Strong evidence base, multiple cleared algorithms, and a partnership model with cardiology practices for remote-monitoring billable workflows.

Apple Watch atrial-fibrillation history and the irregular-rhythm notification feature shipped to a vast consumer install base — the Apple Heart Study and follow-up validation work established the clinical credibility. Samsung Galaxy Watch, Fitbit (Google), and Withings ship comparable algorithms.

iRhythm Zio Patch — long-term continuous ECG monitoring with AI-augmented analysis at scale — anchors the prescribed-monitoring market. Their algorithms process billions of cardiac cycles per year with cardiologist-overread workflows.

Preventice (Boston Scientific) and BioTel Heart (Philips) sit alongside in the prescribed cardiac monitoring space.

Cardiologs (Philips) built deep-learning ECG interpretation that integrates into multiple device manufacturers’ workflows; their AF, ectopy, and arrhythmia algorithms are widely embedded.

Stethoscope and bedside AI#

Eko Health built the AI-augmented digital stethoscope — capturing heart and lung sounds and analysing them for AF, structural heart disease (notably aortic stenosis), and heart-failure features. The FDA cleared their structural-heart-disease and AF algorithms; the use case is the primary-care or community-cardiology workflow where bedside-stethoscope screening can flag patients who need echocardiography. Mayo Clinic collaboration anchored much of the validation work.

Sensora, Acoustic AI, and a handful of regional vendors sit adjacent.

Echocardiography AI#

Echo is the second-largest cardiac imaging modality after ECG, and AI has made meaningful inroads on both acquisition and interpretation.

Caption Health (acquired by GE Healthcare in 2023) anchored the AI-guided acquisition story — a real-time guidance overlay that helps a non-expert operator capture diagnostic-quality echocardiographic views. The Caption Guidance product is FDA-cleared and deployed in primary-care, emergency-department, and rural-care settings as a point-of-care ultrasound (POCUS) augmentation.

Us2.ai built strong automated echo interpretation — wall motion, ejection fraction, valve disease classification — that competes with the OEM-bundled AI from GE, Philips, and Siemens. Their published evidence in heart-failure and structural-heart applications anchors the clinical credibility.

Ultromics anchored the Royal-Brookhouse-derived echo AI story — EchoGo Heart Failure with FDA-cleared automated ejection-fraction quantification.

Philips EchoNavigator and GE EchoPAC AI ship as OEM-bundled stacks; Siemens, Mindray, and Canon Medical compete in the same space.

Coronary CT angiography and the cath-lab referral story#

The biggest clinical-pathway shift of the last five years.

HeartFlow anchored the FFR-CT story — a CT-angiogram-derived functional assessment of coronary stenoses, generating per-vessel fractional flow reserve values from a non-invasive CT. The clinical evidence (PLATFORM, ADVANCE registries) supports a meaningful reduction in invasive catheter-angiogram referrals for patients who can be managed medically. CMS coverage in the US and broad payer coverage in Europe and Japan anchor the commercial model.

Cleerly built the coronary-plaque-characterisation story — quantifying total plaque burden, low-attenuation plaque, and stenosis severity from coronary CT angiography. Strong evidence base around plaque-burden as a prognostic marker independent of stenosis severity. The CLEERLY-CT trial supports the clinical pathway.

Elucid Bioimaging, Caristo Diagnostics (peri-coronary fat-attenuation index, derived from the Oxford CaRi-Heart programme) sit adjacent with niche strengths in plaque inflammation and prognosis.

OEM-bundled CT vendors (GE, Siemens, Canon, Philips) increasingly ship calcium-scoring AI and stenosis-quantification AI natively from the scanner.

Cardiac MR AI#

Circle Cardiovascular Imaging cvi42 and Medis Suite MR anchor the post-processing AI for cardiac MR — automated segmentation of ventricular volumes, ejection fraction, T1/T2 mapping for tissue characterisation, late-gadolinium-enhancement quantification. Arterys (now Tempus) sits in the cloud-based cardiac MR analysis corner.

The clinical context: cardiac MR is the gold-standard for ventricular function and tissue characterisation but is operator-dependent and time-consuming. AI segmentation collapses post-processing time from twenty-plus minutes to single-digit minutes per study, with reproducibility better than manual analysis.

Integration with EHR and cardiology platforms#

Cardiology AI integrates with the existing imaging and reporting platforms — Sectra Cardiology, Philips IntelliSpace Cardiovascular, GE Centricity Cardio Workflow, Change Healthcare Cardiology — and writes results back as structured reports, DICOM SR objects, and discrete data fields that flow into the EHR. The deployment pattern mirrors the radiology AI story: vendor-specific point integrations fail; orchestration via Blackford, Nuance PIN, or vendor-native marketplaces succeed.

Remote-monitoring data (KardiaMobile, Zio, Preventice) flows through dedicated remote-monitoring platforms and increasingly directly into EHR cardiology modules with discrete data fields and billing-code automation.

Regulatory state and reimbursement#

The cardiology AI domain has more reimbursement clarity than most. HeartFlow has CMS coverage and dedicated CPT codes. Multiple AI algorithms have received CPT category III codes (the precursor to permanent reimbursement). Several CMS New Technology Add-On Payment authorisations exist for AI products. European national health systems have made reimbursement decisions on FFR-CT and selected echo AI products. This is one of the meaningfully more developed reimbursement landscapes within healthcare AI.

Where pdpspectra fits#

We help cardiology service lines, imaging centres, and remote-monitoring operations design the integration layer between scanners, ECG devices, AI vendors, cardiology platforms, and EHRs — DICOM routing, structured reporting, remote-monitoring data flows, and the audit and governance the regulated workflow requires. See our data engineering practice.

Related reading#

• AI in clinical trials in 2026
• Healthcare AI playbook: pilot to production
• Hospital data interoperability

If you are scoping a cardiology AI deployment — wearable, echo, CT, MR, or remote monitoring — and want a vendor-neutral read on the operational and integration cost, reach out.